Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMC435 plus PegIFN and Ribavirin in Relapsed Genotype 1 HCV
NCT01290731Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2011
- Primary completion
- Aug 2012
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of simeprevir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Started Jan 2011; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01290731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01290731.